Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies

Study Identifier:
D9282C00003
ClinicalTrials.gov Identifier:
NCT05966467
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
1-855-752-2356 or [email protected]
Recruiting

Study Details

Medical Condition
  • Neuromyelitis Optica Spectrum Disorder
  • NMOSD
  • Unmapped
Study Drug
    Date
    Feb 2024 - Mar 2030
    Phase 1
    Phase 2
    Phase 3
    Phase 4
    N/A
    Patient Requirements
    Sex: Female & Male
    Age: 18+ years
    Requirements Information
    Sex
    Female & Male
    Age
    18+ years

    Study Details

    Medical Condition
    • Neuromyelitis Optica Spectrum Disorder
    • NMOSD
    • Unmapped
    Study Drug
      Date
      Feb 2024 - Mar 2030
      Phase 1
      Phase 2
      Phase 3
      Phase 4
      N/A
      Patient Requirements
      Sex: Female & Male
      Age: 18+ years years
      Requirements Information

      Protocol Summary

      Long-term, multicenter, multinational, observational, registry of patients with AQP4+ NMOSD that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT). The registry will also collect data on patient reported outcomes (PROs), quality of life (QoL), and targeted AQP4+ NMOSD therapies used to provide evidence on the real-world impact of ALXN-C5IT on patients with AQP4+ NMOSD.

      Trial Locations

      Location
      Status
      Location
      Clinical Trial Site
      Washington, District of Columbia, United States, 20010
      Status
      Recruiting
      Location
      Research Site
      Boston, Massachusetts, United States, 02114
      Status
      Recruiting
      Location
      Clinical Trial Site
      Chapel Hill, North Carolina, United States, 27599
      Status
      Not yet recruiting
      Location
      Clinical Trial Site
      Columbus, Ohio, United States, 43215
      Status
      Recruiting
      Location
      Clinical Trial Site
      Plano, Texas, United States, 75024
      Status
      Recruiting
      Location
      Clinical Trial Site
      Milwaukee, Wisconsin, United States, 53215
      Status
      Recruiting